On our screens:R&D leaders
What is the market doing?
What the tape says about ALNY
Alnylam Pharmaceuticals, Inc. is −43% over the past year while the S&P 500 is +20%: 63 points behind the market.
−43%
1-year return · S&P 500 +20%
- vs 200-day average
- −21%
vs 200-day average · a clear downtrend
- RSI (14)
- 71
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 47%
Below its 52-week high
Details›
- Last close2026-09-08
- $260.15
- 1 monthS&P 500 −0.30%
- +20%
- 1 yearS&P 500 +20%
- −43%
- 5 yearsS&P 500 +85%
- +28%
- vs 50-day average$258.98
- +0.45%
- 52-week high
- $491.22
- 52-week low
- $216.46
- Annualised volatility
- 44%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-06-30
- −$16M
| Year | Return |
|---|---|
| 2026 (year to date) | −35% |
| 2025 | +69% |
| 2024 | +23% |
| 2023 | −19% |
| 2022 | +40% |
| 2021 | +30% |
| 2020 | +13% |
| 2019 | +58% |
| 2018 | −43% |
| 2017 | +239% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +0.62% |
| Feb | 10 | 4 of 10 | +0.03% |
| Mar | 10 | 4 of 10 | +1.2% |
| Apr | 10 | 2 of 10 | −3.1% |
| May | 10 | 6 of 10 | +1.0% |
| Jun | 10 | 8 of 10 | +14% |
| Jul | 11 | 6 of 11 | +4.6% |
| Aug | 11 | 9 of 11 | +8.9% |
| Sep | 11 | 5 of 11 | +0.90% |
| Oct | 10 | 4 of 10 | −8.9% |
| Nov | 10 | 8 of 10 | +10% |
| Dec | 10 | 3 of 10 | −3.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
Ranks #89 of 143 by Smart Score